GLPwatch
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Diabetes Res Clin Pract · 2024
Last updated 2026-09-22| Journal | Diabetes Res Clin Pract, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.11 |
| NIH percentile | 8 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 38925293 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.